Sharon Townson - Jan 3, 2023 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Technology Officer
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 03:31 PM
Previous filing
Mar 2, 2022
Next filing
Jun 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +78.6K $0.00 78.6K Jan 3, 2023 Common Stock 78.6K $7.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.